
|Slideshows|July 18, 2018
Seven Most Out-Of-Reach Drugs for Patients Due to High Costs
Author(s)Tracey Walker
Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.
Advertisement
Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
4
TrumpRx launches; some experts question its long-term value
5

























